Abstract

The p53 tumor suppressor protein is a transcription factor that plays a major role in the DNA damage response. After DNA damage, p53 levels increase due primarily to stabilization of the protein. The molecular mechanisms leading to stabilization of p53 after DNA damage have not been completely elucidated. Recently we reported that cisplatin treatment activated extracellular signal-regulated kinase 1 and 2 (ERK1/2) and that inhibition of ERK1/2 resulted in enhanced sensitivity to cisplatin. In the present study, we examined the potential role of ERK1/2 activation in regulation of the p53 response to cisplatin. In the ovarian carcinoma cell line A2780, inhibition of ERK1/2 activation with the mitogen-activated protein kinase/ERK kinase 1 (MEK1) inhibitor PD98059 resulted in decreased p53 protein half-life and diminished accumulation of p53 protein during exposure to cisplatin. We also demonstrated that p53 protein co-immunoprecipitated with ERK1/2 protein and was phosphorylated by activated recombinant murine ERK2 in vitro. Furthermore, PD98059 decreased the phosphorylation of p53 at serine 15 during cisplatin exposure, suggesting that ERK1/2 mediates in part phosphorylation of p53 during the cisplatin DNA response. These results strongly suggest that cisplatin-induced ERK activation is an up-stream regulator of the p53 response to DNA damage caused by cisplatin.

Highlights

  • The p53 tumor suppressor protein is a transcription factor that is activated in response to various types of DNA damage [1,2,3]

  • We reported that cisplatin treatment activated extracellular signal-regulated kinase 1 and 2 (ERK1/2) and that inhibition of ERK1/2 resulted in enhanced sensitivity to cisplatin

  • We showed that cisplatin-induced phosphorylation of p53 at serine 15 is mediated in part by ERK1/2

Read more

Summary

Introduction

The p53 tumor suppressor protein is a transcription factor that is activated in response to various types of DNA damage [1,2,3]. Up-stream kinases that are involved in phosphorylation of p53 at sites near the MDM2 binding domain may participate in MDM2-dependent regulation of p53 accumulation after DNA damage. Fuchs et al [28] demonstrate that c-Jun-N-terminal kinase activation via MAP/ ERK kinase kinase (MEKK1) results in p53 phosphorylation, inhibition of MDM2 association with p53, and an increase in p53 protein half-life. ERK1/2 activity by the MAP/ERK kinase 1 (MEK1) inhibitor PD98059 decreased p53 protein half-life and accumulation during cisplatin treatment in the ovarian carcinoma cell line A2780. We showed that cisplatin-induced phosphorylation of p53 at serine 15 is mediated in part by ERK1/2 These results strongly suggest that ERK1/2 is one of the regulators of p53 protein accumulation and activation during the DNA damage response to cisplatin

Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call